30 closest matches · ranked by relevance
Metastatic gpNMB Over-expressing Triple Negative Breast Cancer
Primary: Progression Free Survival (PFS) — 2.8; 2.9 months — p=0.761
Breast Cancer
Primary: Objective Response Rate — 0.09 proportion of participants
Breast Cancer · Triple Negative Breast Cancer · Stage IV Breast Cancer
Primary: Objective Response Rate — 28; 38 percentage of patients
Breast Cancer
Primary: Clinical Benefit Rate — 0.12 proportion of participants
Triple Negative Breast Cancer
Primary: Efficacy (Objective Response Rate) — 1 Participants
Triple-Negative Breast Cancer
Primary: Percentage of Participants With Treatment-emergent Grade ≥3 Adverse Events (AEs) — 46.70 percentage of participants
Metastatic Triple Negative Breast Cancer
Primary: Overall Response Rate (ORR) in Patients Treated With CNP — 2; 11; 6; 8 Participants
Metastatic Breast Cancer
Primary: Progression-free Survival (PFS) — 4.4 Months
Breast Cancer
Primary: Overall Response Rate — 1 Participants
Estrogen Receptor Negative · HER2/Neu Negative · Invasive Breast Carcinoma
Primary: Objective Response Rate (ORR), Defined as the Proportion of Patients Who Have Had a Partial Response (PR) or Complete Response (CR) (RECIST 1.1 Based) Within the First 6…
Metastatic Triple Negative Breast Cancer
Primary: Objective Response Rate (ORR) — 0; 1; 1; 4 Participants
Triple Negative Breast Cancer
Primary: 3 Months Progression Free Survival. Probability That the Cancer Has Not Progressed at 3 Months Calculated With Kaplan Meier. — 15.8 perceent probability at 3 months
Triple Negative Breast Cancer
Primary: Efficacy (Objective Response Rate) — 3 Participants
Breast Cancer
Primary: Objective Response Rate — 3; 19; 4; 57 Participants
Invasive Breast Carcinoma · Triple-Negative Breast Carcinoma
Primary: RCB Status — 0; 1; 13; 3 participants
Metastatic Non-small Cell Lung Cancer · Metastatic Triple-negative Breast Cancer
Primary: Objective Response Rate — 4; 7; 13; 32 Participants
Breast Cancer
Primary: Objective Response Rate (ORR) (Phase II) — 0; 5; 14 Participants
Breast Cancer
Primary: Best Clinical Response Expressed as Percentage of Participants Treated With Combination Regimen of Weekly Abraxane® and Carboplatin Plus Biweekly Bevacizumab to Treat…
Triple-Negative Breast Cancer
Primary: Progression-Free Survival (PFS) Assessed Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in the Subpopulation With Programmed Death-Ligand 1…
Metastatic Triple Negative Breast Cancer
Primary: Asses the Maximum Tolerated Dose (MTD) of L-NMMA When Combined With Docetaxel/Amlodipine in the Treatment of Refractory Locally Advanced or Metastatic TNBC Patients…
Triple Negative Breast Cancer
Primary: Progression Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v1.1) in All Randomized Participants — 5.49; 7.16 Months…
Malignant Neoplasm of Breast · Breast Cancer
Primary: Percentage of Participants With Two-Year Disease-Free Survival (DFS) — 56.6; 62.4 percentage of participants
Metastatic Breast Cancer
Primary: Progression Free Survival (PFS) After Treatment With Doxil, Carboplatin and Bevacizumab in Patients With ER, PR, HER2neu Negative Metastatic Breast Cancer — 6 participants
Breast Cancer
Primary: Objective Response Rate Per Composite Response Criteria — 7.5; 48.6; 33.3 percent of participants
Metastatic Breast Cancer
Primary: Response Rate (RR) — 4.8; 0 percentage of participants
Stage I Breast Cancer AJCC v7 · Stage IA Breast Cancer AJCC v7 · Stage IB Breast Cancer AJCC v7
Primary: Number of Participants With Residual Disease — 24 Participants
Breast Tumor · Breast Cancer · Cancer of the Breast
Primary: Kaplan-Meier Estimates of Progression-Free Survival (PFS) Based on Investigator Assessment. — 5.5; 8.3; 6.0 months — p=0.0183
Metastatic Breast Cancer
Primary: Number of Participants With and Without Progression Free Survival (PFS) Events — 92; 30 Participants
Breast Cancer
Primary: Rate of Clinical Benefit — 0; 0; 6; 11 Participants
Breast Adenocarcinoma · Metastatic Triple-Negative Breast Carcinoma · Stage III Breast Cancer AJCC v7
Primary: Maximum Tolerated Dose (MTD) of Pembrolizumab in Combination With Binimetinib Using the Standard 3+3 Design (Phase I) — 2; 0; 1; 6 Participants